Moderna, Inc. — Director's Dealing 2024

Aug 29, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2024-08-27

Reporting Person: Mock James M (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-27	Common Stock	M	1326	—	Acquired	8595	Direct
2024-08-27	Common Stock	M	1326	—	Acquired	9921	Direct
2024-08-28	Common Stock	S	1321	$79.3949	Disposed	8600	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-08-27	Performance Stock Units	$	M	1326	Disposed		Common Stock (1326)	Direct
2024-08-27	Restricted Stock Units	$	M	1326	Disposed		Common Stock (1326)	Direct

Footnotes

F1: Performance stock units convert into common stock on a one-for-one basis.

F2: Restricted stock units convert into common stock on a one-for-one basis.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of performance stock units and restricted stock units. This "sell-to-cover" transaction was mandated by the Issuer's equity incentive plan and does not represent a discretionary trade by the reporting person.

F4: 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025.

F5: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter.